Literature DB >> 8160361

Evaluation of several adjuvants as alternatives to the use of Freund's adjuvant in rabbits.

P P Leenaars1, C F Hendriksen, A F Angulo, M A Koedam, E Claassen.   

Abstract

In three experiments we evaluated several types of adjuvants as an alternative to Freund's adjuvant (FA). In the first experiment three adjuvant preparations (a water-in-oil emulsion (Specol), a combination preparation of monophosphoryl lipid A + trehalose dimycolate + cell wall skeleton and a non-ionic block polymer surfactant (TiterMax)) were evaluated. The adjuvants were combined with three different types of weak immunogenic antigens (synthetic peptide, glycolipid and particulate antigen) and administered following the intramuscular and subcutaneous route. The evaluation was based on clinical, pathological and immunological parameters. The animals did not appear to be severely or chronically impaired by the experiment. After injection of the RIBI adjuvant, side effects of the same severity as with FA were induced, while low antibody titers were produced. TiterMax caused few side effects, while antibody responses were very low. In comparing Specol and FA, Specol had far fewer adverse effects than FA. However, Specol had immunostimulating properties of the same level as FA. In the second experiment, the effect of injected volume of FA on side effects and antibody titer was studied. Immunization of rabbits with a total of 0.5 ml FA at different sites does not seem to increase the immune response when compared with the immune response seen after injection of 0.5 ml FA at one site. However side effects were seen in all the animals. In the third experiment, the side effects following intradermal (i.d.) injection of the adjuvants were studied. After i.d. injection of FA or RIBI, undesirable effects were found. No side effects occurred after i.d. injection of Specol or TiterMax. From the studies it is concluded that Specol is an alternative to FA for hyperactivation of the immune response in rabbits.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8160361     DOI: 10.1016/0165-2427(94)90022-1

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  15 in total

1.  Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Elke S Bergmann-Leitner; Leroy N Hwang; Nicholas P Restifo
Journal:  Vaccine       Date:  2006-05-06       Impact factor: 3.641

Review 2.  Animal Models of Ebolavirus Infection.

Authors:  Marisa C St Claire; Dan R Ragland; Laura Bollinger; Peter B Jahrling
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

3.  Quantitation of acute phase proteins and protein electrophoresis in monitoring the acute inflammatory process in experimentally and naturally infected mice.

Authors:  Carolyn Cray; David G Besselsen; Jody L Hart; David Yoon; Marilyn Rodriguez; Julia Zaias; Norman H Altman
Journal:  Comp Med       Date:  2010-08       Impact factor: 0.982

4.  Increased adjuvant efficacy in stimulation of antibody responses after macrophage elimination in vivo.

Authors:  P P Leenaars; H F Savelkoul; C F Hendriksen; N Van Rooijen; E Claassen
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

5.  Cationic Liposome-Oligonucleotide Complex as an Alternative Adjuvant for Polyclonal Antibody Production in New Zealand White Rabbits (Oryctolaguscuniculus).

Authors:  Erin S Lee; Clinton Sc Walker; Jacob E Moskowitz; Valerie A Johnson; Lon V Kendall
Journal:  Comp Med       Date:  2017-12-01       Impact factor: 0.982

6.  A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1.

Authors:  Lisette A H M Cornelissen; Robert P de Vries; Els A de Boer-Luijtze; Alan Rigter; Peter J M Rottier; Cornelis A M de Haan
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

7.  Comparative assessment of cultured skin substitutes and native skin autograft for treatment of full-thickness burns.

Authors:  S T Boyce; M J Goretsky; D G Greenhalgh; R J Kagan; M T Rieman; G D Warden
Journal:  Ann Surg       Date:  1995-12       Impact factor: 12.969

8.  Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.

Authors:  Guillaume Goyette-Desjardins; Cynthia Calzas; Tze Chieh Shiao; Axel Neubauer; Jennifer Kempker; René Roy; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

9.  Antibody production in rabbits administered Freund's complete adjuvant and carprofen concurrently.

Authors:  Joanna E Fishback; Sabrina M Stronsky; Catherine A Green; Krystal D Bean; Jeffrey W Froude
Journal:  Lab Anim (NY)       Date:  2016-02       Impact factor: 12.625

10.  Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit.

Authors:  Kongnara Papangkorn; Eri Prendergast; John W Higuchi; Balbir Brar; William I Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2017-10-12       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.